Serenex, a biotechnology company applying chemoproteomic technologies to drug discovery, has named Gunnar Hanson as its director of chemistry.

Hanson joins Durham-based Serenex from Pfizer, where he recently served as senior research advisor and fellow. He also led the Renin Inhibitor Project at the New York-based pharmaceutical company.

“We welcome Gunnar as a valuable addition to our management and scientific team,” said Richard Kent, president and CEO of Serenex. “His knowledge and experience in drug discovery and development will contribute greatly to Serenex. Our internal drug discovery programs have made great progress and will benefit from Dr. Hanson’s extensive expertise to continue on their aggressive timelines.”

Hanson earned his B.S. at the University of Oregon and his Ph.D. at MIT, and held a postdoctoral fellowship at Stanford University. He has authored over 20 scientific papers and is named as inventor on over 120 issued U.S. patents.